Photon Therapeutics, has been named the winner of the Technology Award at the AHNTI EU Innovation Showcase 2026, recognising its breakthrough approach to advancing animal health innovation.
BioAZ is proud to announce a $1M (€900k) fundraising round with the support of its historical shareholders and leading veterinary business angels.
Pioneering molecular diagnostics company MI:RNA, which uses biomarkers and advanced modelling to diagnose veterinary disease earlier, has reached a growth milestone with the completion of an oversubscribed funding round.
Antigenesis joins the AHA portfolio with a focus on creating targeted antibody-based cancer treatments for pets. With early funding secured and lead molecules in preclinical development, the company is working to bring new options to a fast-growing area of veterinary medicine.
We are delighted to congratulate SageTech Medical, one of our portfolio companies, on securing £3.6 million in funding through Innovate UK's prestigious Grand Challenge programme.
Antimicrobial resistance (AMR) is one of the defining challenges of our time. It affects animal health and welfare in practice and has profound potential consequences for human health. As vets, we understand the pressure to reduce reliance on antibiotics while still safeguarding our patients. Animal Health Angels, a group of veterinary and animal health professionals supporting early-stage innovation, has announced recent backing for three companies developing practical solutions to tackle AMR and antibiotic use in clinical settings: Zonova, FluoretiQ and NoBACZ.
